MRI Texture Analysis Predicts p53 Status in Head and Neck Squamous Cell Carcinoma

References

1. 1.↵
   2. Parkin DM,
   3. Bray F,
   4. Ferlay J, et al

   . Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Ang KK,
   3. Sturgis EM

   . Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012;22:128–42

   CrossRefPubMed
3. 3.↵
   American Joint Committee on Cancer. Cancer Staging Handbook: From the AJCC Cancer Staging Manual. Berlin: Springer-Verlag; 2010
4. 4.↵
   2. Bauman JE,
   3. Michel LS,
   4. Chung CH

   . New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012;24:235–42

   CrossRefPubMed
5. 5.↵
   2. Lane DP

   . Cancer: p53, guardian of the genome. Nature 1992;358:15–16

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Levine AJ,
   3. Momand J,
   4. Finlay CA

   . The p53 tumour suppressor gene. Nature 1991;351:453–56

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Levine AJ,
   3. Perry ME,
   4. Chang A, et al

   . The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409–16

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Hollstein M,
   3. Sidransky D,
   4. Vogelstein B, et al

   . p53 mutations in human cancers. Science 1991;253:49–53

   Abstract/FREE Full Text
9. 9.↵
   2. Vogelstein B

   . Cancer: a deadly inheritance. Nature 1990;348:681–82

   CrossRefPubMed
10. 10.↵
    2. Kozomara R,
    3. Jovic N,
    4. Magic Z, et al

    . p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg 2005;33:342–48

    CrossRefPubMed
11. 11.↵
    2. Smith EM,
    3. Wang D,
    4. Rubenstein LM, et al

    . Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomarkers Prev 2008;17:421–27

    Abstract/FREE Full Text
12. 12.↵
    2. Soussi T,
    3. Béroud C

    . Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233–40

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Poeta ML,
    3. Manola J,
    4. Goldwasser MA, et al

    . TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552–61

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Skinner HD,
    3. Sandulache VC,
    4. Ow TJ, et al

    . TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18:290–300

    Abstract/FREE Full Text
15. 15.↵
    2. De Schepper AM,
    3. De Beuckeleer L,
    4. Vandevenne J, et al

    . Magnetic resonance imaging of soft tissue tumors. Eur Radiol 2000;10:213–23

    CrossRefPubMed
16. 16.↵
    2. Gielen JL,
    3. De Schepper AM,
    4. Vanhoenacker F, et al

    . Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions: a prospective study in 548 patients. Eur Radiol 2004;14:2320–30

    CrossRefPubMed
17. 17.↵
    2. Kransdorf MJ,
    3. Murphey MD

    . Radiologic evaluation of soft-tissue masses: a current perspective. AJR Am J Roentgenol 2000;175:575–87

    CrossRefPubMed
18. 18.↵
    2. Sundaram M,
    3. McGuire MH,
    4. Herbold DR

    . Magnetic resonance imaging of soft tissue masses: an evaluation of fifty-three histologically proven tumors. Magn Reson Imaging 1988;6:237–48

    CrossRefPubMed
19. 19.↵
    2. Mahmoud-Ghoneim D,
    3. Toussaint G,
    4. Constans JM, et al

    . Three dimensional texture analysis in MRI: a preliminary evaluation in gliomas. Magn Reson Imaging 2003;21:983–87

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Zhang Y

    . MRI texture analysis in multiple sclerosis. Int J Biomed Imaging 2012;2012:762804

    PubMed
21. 21.↵
    2. Chang CW,
    3. Ho CC,
    4. Chen JH

    . ADHD classification by a texture analysis of anatomical brain MRI data. Front Syst Neurosci 2012;6:66

    PubMed
22. 22.↵
    2. Zhang J,
    3. Yu C,
    4. Jiang G, et al

    . 3D texture analysis on MRI images of Alzheimer's disease. Brain Imaging Behav 2012;6:61–69

    CrossRefPubMed
23. 23.↵
    2. Weyn B,
    3. van de Wouwer G,
    4. van Daele A, et al

    . Automated breast tumor diagnosis and grading based on wavelet chromatin texture description. Cytometry 1998;33:32–40

    CrossRefPubMed
24. 24.↵
    2. Schilling T,
    3. Miroslaw L,
    4. Glab G, et al

    . Towards rapid cervical cancer diagnosis: automated detection and classification of pathologic cells in phase-contrast images. Int J Gynecol Cancer 2007;17:118–26

    CrossRefPubMed
25. 25.↵
    2. Brown R,
    3. Zlatescu M,
    4. Sijben A, et al

    . The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–62

    Abstract/FREE Full Text
26. 26.↵
    2. Eoli M,
    3. Menghi F,
    4. Bruzzone MG, et al

    . Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007;13:2606–13

    Abstract/FREE Full Text
27. 27.↵
    2. Levner I,
    3. Drabycz S,
    4. Roldan G, et al

    . Predicting MGMT methylation status of glioblastomas from MRI texture. Med Image Comput Comput Assist Interv 2009;12:522–30

    PubMed
28. 28.↵
    2. Drabycz S,
    3. Stockwell RG,
    4. Mitchell JR

    . Image texture characterization using the discrete orthonormal S-transform. J Digit Imaging 2009;22:696–708

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Yu H,
    3. Caldwell C,
    4. Mah K, et al

    . Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 2009;28:374–83

    CrossRefPubMed
30. 30.↵
    NeoLogica. DICOM Anonymizer Pro. http://www.neologica.it/eng/DICOMAnonymPro.php. Accessed September 12, 2012.
31. 31.↵
    2. Cheng CH,
    3. Mitchell JR

    . Fast Time-Frequency Transform in 2D (FTFT-2D). IET Signal Processing 2014;8:360–72

    CrossRef
32. 32.↵
    2. Frank E,
    3. Hall M,
    4. Trigg L, et al

    . Data mining in bioinformatics using Weka. Bioinformatics 2004;20:2479–81

    Abstract/FREE Full Text
33. 33.↵
    2. Gutlein M,
    3. Frank E,
    4. Hall M, et al

    . Large-scale attribute selection using wrappers. In: Proceedings of IEEE Symposium on Computational Intelligence and Data Mining, Nashville, Tennessee. March 30 to April 2, 2009. Washington: IEEE Computer Society; 2009:332–39
34. 34.↵
    2. Cheng J,
    3. Greiner R

    . Comparing Bayesian network classifiers. In: Proceedings of the Fifteenth Conference on Uncertainty in Artificial Intelligence, Stockholm, Sweden. July 30–31, 1999:101–08
35. 35.↵
    2. Heckerman D

    . Bayesian networks for data mining. Data Mining and Knowledge Discovery 1997;1:79–119

    CrossRefWeb of Science
36. 36.↵
    2. Hruschka ER Jr.,
    3. Hruschka ER,
    4. Ebecken NF

    . Bayesian networks for imputation in classification problems. Journal of Intelligent Information Systems 2007;29:231–52

    CrossRef
37. 37.↵
    2. Liu C,
    3. Zhang H,
    4. Pan Y, et al

    . Towards MIB-1 and p53 detection in glioma magnetic resonance image: a novel computational image analysis method. Phys Med Biol 2012;57:8393–404

    CrossRefPubMed
38. 38.↵
    2. Fruehwald-Pallamar J,
    3. Czerny C,
    4. Holzer-Fruehwald L, et al

    . Texture-based and diffusion-weighted discrimination of parotid gland lesions on MR images at 3.0 Tesla. NMR Biomed 2013;26:1372–79

    CrossRefPubMed
39. 39.↵
    2. Mayerhoefer ME,
    3. Schima W,
    4. Trattnig S, et al

    . Texture-based classification of focal liver lesions on MRI at 3.0 Tesla: a feasibility study in cysts and hemangiomas. J Magn Reson Imaging 2010;32:352–59

    CrossRefPubMed
40. 40.↵
    2. Shi Z,
    3. Yang Z,
    4. Zhang G, et al

    . Characterization of texture features of bladder carcinoma and the bladder wall on MRI: initial experience. Acad Radiol 2013;20:930–38

    CrossRefPubMed
41. 41.↵
    2. Guo R,
    3. Li Q,
    4. Meng L, et al

    . P53 and vascular endothelial growth factor expressions are two important indices for prognosis in gastric carcinoma. West Indian Med J 2008;57:2–6

    PubMed
42. 42.↵
    2. Riedel F,
    3. Götte K,
    4. Schwalb J, et al

    . Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol 2000;120:105–11

    PubMed
43. 43.↵
    2. Uchida S,
    3. Shimada Y,
    4. Watanabe G, et al

    . In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704–09

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Ahmed A,
    3. Gibbs P,
    4. Pickles M, et al

    . Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 2013;38:89–101

    CrossRefPubMed